ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
China NMPA Approves Phase III Clinical Trial of ASC40 Combined with Bevacizumab for Treatment of Patients with Recurrent Glioblastoma
July 22, 2021Ascletis Pharma Inc. today announces that China National Medical Products Administration (NMPA) has approved the Phase III clinical trial application of ASC40 combined with Bevacizumab for treatment of patients with recurrent glioblastoma. -
Sagimet Biosciences Receives Fast Track Designation from FDA for NASH Treatment
March 24, 2021Sagimet Biosciences announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to TVB-2640 for the treatment of patients with NASH.
Pharma Sources Insight January 2025
